231 related articles for article (PubMed ID: 37493758)
21. Placebo Response in Rheumatoid Arthritis Clinical Trials.
Bechman K; Yates M; Norton S; Cope AP; Galloway JB
J Rheumatol; 2020 Jan; 47(1):28-34. PubMed ID: 31043548
[TBL] [Abstract][Full Text] [Related]
22. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Alten R; Mischkewitz M; Stefanski AL; Dörner T
Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
[TBL] [Abstract][Full Text] [Related]
23. [Small molecules treatment in rheumatoid arthritis].
Verdon A; Lauper K
Rev Med Suisse; 2020 Mar; 16(685):477-480. PubMed ID: 32167248
[TBL] [Abstract][Full Text] [Related]
24. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
Singh S; Singh S
Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
[TBL] [Abstract][Full Text] [Related]
25. Start RA treatment - Biologics or JAK-inhibitors?
Caporali R; Germinario S; Kacsándi D; Choy E; Szekanecz Z
Autoimmun Rev; 2024 Jan; 23(1):103429. PubMed ID: 37634678
[TBL] [Abstract][Full Text] [Related]
26. Evaluating upadacitinib for the treatment of rheumatoid arthritis.
Mysler E; Lizarraga A
Expert Opin Pharmacother; 2020 Sep; 21(13):1527-1536. PubMed ID: 32515665
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
28. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2018 Jul; 60(1552):123-128. PubMed ID: 30044766
[No Abstract] [Full Text] [Related]
29. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
[TBL] [Abstract][Full Text] [Related]
30. [DMARD (disease-modifying antirheumatic drug) treatment in patients with former or current cancer].
Krüger K
Z Rheumatol; 2023 Apr; 82(3):206-211. PubMed ID: 36757415
[TBL] [Abstract][Full Text] [Related]
31. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
Redeker I; Albrecht K; Kekow J; Burmester GR; Braun J; Schäfer M; Zink A; Strangfeld A
Ann Rheum Dis; 2022 Jan; 81(1):41-47. PubMed ID: 34321218
[TBL] [Abstract][Full Text] [Related]
32. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
33. Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States.
Curtis JR; Xie F; Yang S; Danila MI; Owensby JK; Chen L
J Rheumatol; 2019 Mar; 46(3):237-244. PubMed ID: 30442830
[TBL] [Abstract][Full Text] [Related]
34. [Biologics and further new drugs for rheumatic diseases since 2000].
Krüger K
Orthopade; 2018 Nov; 47(11):906-911. PubMed ID: 30280235
[TBL] [Abstract][Full Text] [Related]
35. Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2021 May; 38(5):2750-2756. PubMed ID: 33742364
[No Abstract] [Full Text] [Related]
36. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
39. [JAK inhibitors in the management of rheumatoid arthritis].
Finckh A
Rev Med Suisse; 2019 Mar; 15(641):528-532. PubMed ID: 30860322
[TBL] [Abstract][Full Text] [Related]
40. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada S; Kubo S; Iwata S; Tanaka Y
BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
